latest update:
[TrialBase DB]

trial summary · NCT07872020

SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Aortic Valve Stenosis and/or Insufficiency, sponsored by Erasmus Medical Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07872020phase —enrollment 422start 2026-10-26

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Rationale: Transcatheter aortic valve implantation (TAVI) has become the standard of care for aortic stenosis across all surgical risk categories, including low-risk, younger patients (≥70 years). As many of these patients are expected to outlive their prosthetic valves, the durability of the valve becomes an increasingly critical factor. Hypoattenuated leaflet thickening (HALT), a finding on post-TAVI computed tomography (CT), occurs in approximately 20% of patients and is associated with bioprosthetic valve dysfunction. Balloon-expandable valves seem more susceptible to HALT with an occurrence rate of 21%, compared to 16% for self-expanding valves. A recent study identified underexpansion of the transcatheter heart valve prosthesis as a key predictor of HALT at 30 days, which in turn was associated with a sixfold increase in cardiovascular mortality and a threefold increase in all-cause mortality at 1 year. Moreover, data suggest that, in the absence of post-dilatation, more than 95% of balloon-expandable valve implants exhibit some degree of underexpansion. In contrast, routine post-dilatation enhances valve expansion and hemodynamic performance without significantly increasing adverse events. The double-TAP technique-re-inflation of the TAVI delivery balloon after initial valve deployment-achieves a 9-10% increase in valve frame expansion, potentially reducing HALT risk and improving long-term outcomes. Objective: To determine whether routine double-TAP post-dilatation after balloon-expandable TAVI is safe and can reduce the incidence of HALT. Study design …

Source record: https://clinicaltrials.gov/study/NCT07872020

Facts

registry idNCT07872020
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionAortic Valve Stenosis and/or Insufficiency
sponsorErasmus Medical Center
sponsor classOTHER
enrollment422
start date2026-10-26
primary completion2028-11-01
completion2033-11-01
results postednot reported

Conditions

  • Aortic Valve Stenosis and/or Insufficiency
  • Hypoattenuated Leaflet Thickening
  • Valve Expansion
  • Transcatheter Aortic Valve Replacement

Interventions

  • Double-TAP post-dilatation

Countries

  • Germany
  • Netherlands

Intervention types: PROCEDURE

Work with this record